
What Osterwalder gets wrong (and right) about innovation metrics
What does the firm behind the business model canvas have to say about innovation metrics?
Better measurement for innovation
What does the firm behind the business model canvas have to say about innovation metrics?
A recently published study, by Ilse Svensson de Jong, highlights three problems with innovation metrics that can seriously hurt firms’ innovation efforts.
A recent HBR article (here) claims that use of innovation metrics (especially financial metrics) too early will “suffocate” your most promising innovations. The author, Scott
Pharmaceutical firms drove R&D investment higher by nearly 12% in Q4 of 2020.
Innovation spending grew strongly in Q3. But how will your competitors respond to increasing pressure on budgets as the economic outlook worsens? Review their spending patterns in our data visualization tool.
What will AI mean for innovation productivity? We review the fundamentals (which look strong) and some examples of AI in innovation (which are exciting, but lack high-quality data on impact).
Innovation teams are facing budget constraints for the remainder of 2020 and into 2021. But the impact of COVID-19 means innovation is more important than ever. Act now to bolster the case for sustained investment in innovation.
Many firms are updating their innovation strategies in response to COVID-19. Those changes will only be implemented if they are effectively communicated.
With a recession imminent, innovation leaders will soon be facing budget pressure. We look back at R&D spending in recent US recessions to understand what might be coming—and consider how to prepare.
Our advice to organizations who are deciding to do something to improve their innovation performance measurement system, including when to do it in-house and when to get outside help.
What does the firm behind the business model canvas have to say about innovation metrics?
A recently published study, by Ilse Svensson de Jong, highlights three problems with innovation metrics that can seriously hurt firms’ innovation efforts.
A recent HBR article (here) claims that use of innovation metrics (especially financial metrics) too early will “suffocate” your most promising innovations. The author, Scott
Pharmaceutical firms drove R&D investment higher by nearly 12% in Q4 of 2020.
Innovation spending grew strongly in Q3. But how will your competitors respond to increasing pressure on budgets as the economic outlook worsens? Review their spending patterns in our data visualization tool.
What will AI mean for innovation productivity? We review the fundamentals (which look strong) and some examples of AI in innovation (which are exciting, but lack high-quality data on impact).
Innovation teams are facing budget constraints for the remainder of 2020 and into 2021. But the impact of COVID-19 means innovation is more important than ever. Act now to bolster the case for sustained investment in innovation.
Many firms are updating their innovation strategies in response to COVID-19. Those changes will only be implemented if they are effectively communicated.
With a recession imminent, innovation leaders will soon be facing budget pressure. We look back at R&D spending in recent US recessions to understand what might be coming—and consider how to prepare.
Our advice to organizations who are deciding to do something to improve their innovation performance measurement system, including when to do it in-house and when to get outside help.
Copyright © 2023 · All Rights Reserved · New